

Open Peer Review on Qeios

Labetuzumab-SN-38 Immunoconjugate IMMU-130

National Cancer Institute

Source

National Cancer Institute. <u>Labetuzumab-SN-38 Immunoconjugate IMMU-130</u>. NCI Thesaurus. Code C95710.

An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent topoisomerase I inhibitor SN-38, with antineoplastic activity. The monoclonal antibody moiety of antibody-drug conjugate IMMU-130 selectively binds to carcinoembryonic cell adhesion molecule 5 (CEACAM5), which is abundantly expressed on the surface of a majority of solid tumors. Upon internalization and proteolytic cleavage, SN-38, the active metabolite of irinotecan, inhibits the activity of topoisomerase I in the tumor cells, eventually inhibiting both DNA replication and transcription and leading to tumor cell apoptosis.

Qeios ID: CS1IAE · https://doi.org/10.32388/CS1IAE